PCVX
VaxcyteDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings company update was supportive in the limited sense that the adult Phase 3 program is now fully enrolled, OPUS-1 timing stayed on track for Q4 2026, and the balance sheet remains unusually strong for a clinical-stage biotech at roughly $2.7 billion of cash and investments. If investors view the May update as confirming execution rather than slipping timelines, the stock can continue to trade off the possibility that successful VAX-31 data would create a best-in-class adult PCV asset.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.0.
What can break
Cash burn increased materially in Q1 2026 as R&D expense rose to $312.8 million, so even a strong cash balance does not eliminate financing sensitivity if timelines extend or development costs rise further.
Momentum
15
Value
41
Sentiment
88
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $63.00 · Bull $92.00 · Bear $38.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $109.00
Why
Momentum15 · Δ7d +1.5
Value41 · Δ7d +0.1
Sentiment88 · Δ7d -1.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
15
34% active weight
Current posture
7d trendFlat
Δ7d
+1.5
Δ21d
-22.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
88
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
+17.7
Why this grade
Composite grade D. Momentum 15.0 / Value 41.1 / Sentiment 87.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$7.06B
Beta
1.33
Shares Out
130.91M
P/E (TTM) · Derived
-9.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.80
Rev YoY
-
EPS YoY
-87.4%
Gross Margin
-
Op Margin
-
Net Debt
-$1.75B
Current Ratio
8.83
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology